Suzhou, China-based Ascentage Pharma Group International, a biopharmaceutical company focused on developing therapies for hematological malignancies, has priced its initial public offering of 7.33 million American depositary shares or ADSs at $17.25 per ADS.
The ADSs will begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol "AAPGV," with regular trading expected to commence on January 27, 2025, under the ticker symbol "AAPG."
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.